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Background: Methylphenidate (MP) is a dopamine- and noradrenaline-enhancing agent 
beneﬁ  cial for post-stroke depression (PSD) and stroke recovery due to its therapeutic effects on 
cognition, motivation, and mood; however, the neural mechanisms underlying its clinical effects 
remain unknown. This study used functional magnetic resonance imaging (f MRI) to investigate 
the effect of MP on brain activity in response to cognitive tasks in patients with PSD.
Methods: Nine stroke outpatients with DSM IV deﬁ  ned major depression underwent fMRI 
during two cognitive tasks (2-back and serial subtraction) on four occasions, on the ﬁ  rst and third 
day of a three-day treatment of MP and placebo. Nine healthy control (HC) subjects matched 
for age and sex scanned during a single session served as normative data for comparison. The 
main outcome measure was cognitive task-dependent brain activity.
Results: For the 2-back task, left prefrontal, right parietal, posterior cingulate, and temporal 
and bilateral cerebellar regions exhibited signiﬁ  cantly greater activity during the MP condition 
relative to placebo. Less activity was detected in rostral prefrontal and left parietal regions. 
For serial subtraction, greater activity was detected in medial prefrontal, biparietal, bitemporal, 
posterior cingulate, and bilateral cerebellar regions, as well as thalamus, putamen, and insula. 
Further, underactivation observed during the placebo condition relative to HC improved or 
reversed during MP treatment. No signiﬁ  cant differences in behavioral measures were found 
between MP and placebo conditions or between patients and HC.
Conclusions: Short-term MP treatment may improve and normalize activity in cognitive 
neuronal networks in patients with PSD.
Keywords: methylphenidate, post-stroke depression, functional MRI, cognition
Depression is the most common and severe mood disorder following stroke. 
Approximately 30% to 50% of stroke patients may suffer from depression during the 
ﬁ  rst two years after a stroke (Robinson 1998b). Depression following stroke adversely 
affects post-stroke physical and cognitive functioning and long term survival, which can 
be remedied by treating the depression (Gonzalez-Torrecillan et al 1995; Ramasubbu 
et al 1998; Kimura et al 2000; Jorge et al 2003). Hence, recognition and effective 
treatment of post-stroke depression (PSD) is crucial to reduce disease burden, morbidity 
and mortality in stroke patients. Enhancement of central catecholaminergic activity 
has been considered as a potential treatment strategy for PSD, based on the evidence 
from clinical and preclinical studies implicating catecholamine deﬁ  cits in the etiology 
of PSD (Robinson and Bloom 1977; Barry and Dinan 1990; Bryer et al 1992).
One suggested approach to improve the catecholamine system in PSD is the use 
of psychostimulants, such as methylphenidate (MP), which is a potent dopamine and Neuropsychiatric Disease and Treatment 2008:4(6) 1252
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noradrenergic reuptake inhibitor (Kuczemski and Segal 1997). 
MP is widely used to treat children and adults with attention 
deﬁ  cit hyperactivity disorder. It is also recommended in the 
treatment of depression in speciﬁ  c patient sub-groups, such 
as depression secondary to brain injury, geriatric depression 
and resistant depression, where cognitive and motivational 
deﬁ  cits are predominant (Hallman and Lipsky 2000; Orr and 
Taylor 2007). MP has been successfully used to alleviate PSD 
and to enhance post-stroke recovery. A series of retrospective 
studies and one double-blind placebo-controlled study have 
suggested the efﬁ  cacy and safety of MP in the treatment of 
PSD and also in the acceleration of stroke recovery (Masand 
et al 1991; Johnson et al 1992; Lazarus et al 1992, 1994; 
Grade et al 1998). MP treatment is advantageous over 
antidepressants as it produces rapid clinical response within 
three to ten days after the initiation of treatment at a mean 
dose of 17 mg/d (Masand et al 1991).
The therapeutic effects of MP in the treatment of 
depression have been attributed to its ability to improve mood, 
motivation and other cognitive functions including attention, 
working memory and executive functions (Hallman and 
Lipsky 2000). In support of its cognitive effects, preclinical 
and clinical studies have shown that MP is effective in 
improving working memory (WM), attention, and alertness 
(Hallman and Lipsky 2000; Wright and White 2003; Orr and 
Taylor 2007). Cognitive impairment is frequently associated 
with post stroke major depression and the nature of the 
relationship between cognitive impairment and post stroke 
depression remains complex (Robinson 1998a). Thus cogni-
tive impairment may be a cause or effect or both (cause and 
effect) in relation to PSD. Furthermore, cognitive impairment 
and depression may be independent consequences of stroke. 
Given that major depression is frequently associated with 
cognitive impairment in stroke patients and MP is beneﬁ  cial 
for both depression and related cognitive impairments, MP 
may have a role in the treatment of PSD with cognitive 
dysfunction (Robinson 1998b). However, the cognitive 
effects of MP in patients with PSD and their underlying 
neural mechanisms have not been well studied.
In this experiment, we examined the effects of short-
term MP administration on behavioral performances 
and hemodynamic (blood oxygenation level-dependent; 
BOLD) responses during working memory and mental 
arithmetic (subtraction) cognitive tasks in patients with 
PSD, employing a double-blind placebo-controlled within-
subject design. Based on previous observations (Mehta et al 
2000; Volkow et al 2004), we predicted that in patients with 
PSD, MP short-term treatment, as compared to placebo, 
would improve and normalize BOLD responses in neuronal 
networks especially in parietal and frontal areas activated 
by the working memory and mental subtraction tasks as in 
healthy subjects. We also predicted that changes in BOLD 
responses induced by MP would be correlated with changes 
in task performance and mood.
Methods
This study was approved by the conjoint research ethics 
board governing the institution, and all subjects gave written 
informed consent prior to their participation.
Subjects
Nine right-handed patients (5 females, 4 males; mean 
age = 50.5 years; range 40–70 years) with DSM IV deﬁ  ned 
major depression due to stroke (APA 2000) participated in 
the study. The handedness was determined by the Edinburgh 
handedness inventory (Oldﬁ  eld 1971). Patients had identiﬁ  able 
ischemic stroke lesions involving middle cerebral artery 
(MCA) and/or anterior cerebral artery (ACA) territories, as 
determined by clinical imaging. Subjects with PSD were 
recruited from a cohort of patients referred to the “Post-
Stroke Depression Clinic” at the Foothills Medical Centre 
afﬁ  liated with the Faculty of Medicine, University of Calgary, 
Calgary, Canada. DSM IV diagnosis of major depression was 
determined by structured clinical interview (SCID) (First et al 
1997). The Mini-Mental State Exam (MMSE) and Barthel 
Index were used to measure cognitive and physical functioning 
respectively (Mahoney and Barthel 1965; Folstein et al 1975). 
Lesion characteristics, medications and medical illnesses were 
obtained from medical charts. The exclusion criteria were: 
i) severe communication and cognitive deﬁ  cits (MMSE   20); 
ii) less than grade 12 education; iii) neurological conditions 
(epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple 
sclerosis, or severe head injury); iv) medical conditions (active 
cancer, renal or liver failure, unstable diabetes mellitus, or 
hypertension); v) psychiatric conditions other than depression 
(psychosis, current substance abuse, or obsessive compulsive 
disorder); vi) current use of antidepressants, antipsychotics 
or mood stabilizers; vii) patients with prestroke depression 
that continued during poststroke period; viii) contradictions 
for MRI. Since sleep deprivation may affect cognitive 
performance, patients were allowed to take Zopiclone (5 mg 
to 7.5 mg) for insomnia, if needed.
Nine right-handed healthy volunteers served as control 
subjects, matched for age and gender to the patient group. Sub-
jects in the healthy comparison group were recruited from the 
local hospital environment, nursing and administrative staff.Neuropsychiatric Disease and Treatment 2008:4(6) 1253
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All subjects were free of any major neurological or medical 
problems, as determined by self-report and detailed inter-
view. The absence of psychiatric illness in healthy controls 
was ascertained by SCID (First et al 1997).
Experimental design
Subjects with PSD participated in four f MRI sessions: on 
the ﬁ  rst and third day of a three-day placebo treatment and 
on the ﬁ  rst and third day of a three-day MP treatment. The 
study was conducted using a double-blind crossover design 
with sessions of placebo and MP treatment approximately 
one week apart. The order of placebo and MP conditions 
were counterbalanced across subjects to control for practice 
effects on the performance of cognitive tasks. Owing 
to the ethical considerations of giving MP to healthy 
elderly controls, subjects in the comparison group were 
scanned during a single session without a placebo or MP 
treatment.
Drug dose and administration
Patients with PSD were given oral MP 20 mg (slow release) 
and placebo (lactulose), presented in identical capsules. 
Patients were asked to take MP or placebo at a ﬁ  xed time 
between 6 and 8 am in the morning, after a light breakfast 
and without any beverages containing caffeine for three 
consecutive days. Caffeine is a psychostimulant with a 
physiological half-life of   3.5 hours (Parsons and Neims 
1978), and may augment the effect of MP, potentially 
complicating the ﬁ  ndings of the study. Patients were advised 
to adhere to the same time schedule for MP and placebo intake 
for subsequent imaging sessions of the study. Approximately 
4 hours after administration of MP or placebo, imaging was 
performed between 10 to 12 am for all subjects. Consider-
ing the rapid clinical response to MP in PSD (Masand et al 
1991), this study design included only three days of treatment. 
Further, the short-term treatment was preferred to minimize 
the length of placebo exposure for ethical reasons and also to 
limit the carry-over effects of clinical recovery in a crossover 
design. The dose of 20 mg of MP selected for this study was 
based upon previous reports documenting its therapeutic 
efﬁ  cacy at a mean dose of 17 mg per day in PSD (Masand 
et al 1991). We did not choose the dose based on weight, as 
there are no clear guidelines for weight-adjusted doses in 
elderly patients. Slow release was chosen as it allowed us to 
have a ﬂ  exible drug latency period of 4 hours between MP 
administration and imaging. The time to peak for slow release 
MP is 4.7 hours (1.3 to 8.2 hrs) and 1.9 hrs (0.3 to 4.4 hrs) 
for regular MP tablets (Liu et al 2005).
Pre-scanning procedure
Subjects were requested to abstain from alcohol for at least 
24 hours prior to the f MRI session, as ethanol interacts with 
MP, elevating metabolite levels and potentially adversely 
affecting cognitive function (Patrick et al 2007). All subjects 
were given instructions about the two cognitive tasks and 
were given off-line practice trials to familiarize themselves 
with the tasks. A different set of task stimuli were used for 
the scanning session. Blood pressure and pulse rate were 
measured before each scanning session (pulse rate during 
scanning could not be monitored due to technical problems). 
Hamilton Depression Rating Scale (HDRS) (Hamilton 
1960), Visual Analogue Scale (VAS) (Grunhaus et al 2002), 
and MMSE were used to measure depression severity and 
cognitive functioning prior to scanning.
Cognitive tasks
The N-back task is commonly used to investigate the neural 
basis of working memory. Mental subtraction task is a multi-
component cognitive task to evaluate attention, calculation 
and working memory and executive functions. The purpose 
of using two cognitive tasks was to evaluate the neural 
networks of wide range of cognitive functions. Both tasks 
are known to activate a distributed network of brain areas 
including frontal and parietal regions (Rueckert et al 1996; 
Burbaud et al 1999; Owen et al 2005). Prior imaging studies 
have demonstrated abnormalities in frontal and parietal 
neural networks in patients with major depression during the 
performance of N-back and mental arithmetic tasks (Hugdahl 
et al 2004; Matsuo et al 2007).
Stimuli preparation
All task stimuli were created and presented using Presenta-
tion (Neurobehavioral Systems Inc., Albany, CA), and were 
viewed by subjects in the MR scanner using liquid crystal 
display goggles (Resonance Technology Inc., Parthenia, CA). 
Behavioral responses requiring a button press were recorded 
using an MR-compatible four-button keypad (Compumedics 
Neuroscan Inc., El Paso, TX).
2-back task
Subjects were presented with a series of single digits at 
3-second intervals within 30-second blocks (Awh et al 
1996). Subjects were asked to respond using the keypad 
when the current digit was the same as that presented two 
digits previously. Alternating 30-second blocks consisted of 
a blank grey screen with a ﬁ  xation cross and the word “TAP” 
was presented at pseudo-random intervals to instruct the Neuropsychiatric Disease and Treatment 2008:4(6) 1254
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participant to respond with the keypad. Four blocks of task 
and ﬁ  ve blocks of control task (TAP) were completed during 
each run, and two runs were performed for this task.
Mental subtraction task
In this task, subjects performed two types of subtrac-
tion, simple subtraction (SIMSUB) and serial subtraction 
(SERSUB), alternating in 30-second blocks. SIMSUB con-
sisted of ten trials of visually presented subtraction opera-
tions (eg, 56-1), presented at 3-second intervals. A SERSUB 
block consisted a 3-second presentation of a two digit base 
number, and every 3 seconds thereafter, the operation to be 
performed appeared (eg, −1). Subjects were asked to perform 
this operation on the result of the previous operation. Each 
30-second block of both tasks consisted of either subtracting 
the number 1 or the number 7 as a means to modulate the dif-
ﬁ  culty of the task. As a result, the blocks were in the following 
order: SIMSUB_1, SERSUB_1, SIMSUB_7, SERSUB_7, 
SIMSUB_1, SERSUB_1, SIMSUB_7, SERSUB_7, SIMSUB_1, 
SERSUB_1, SIMSUB_7, SERSUB_7, SIMSUB_1. During 
each block of ten trials, two pseudo-randomly chosen trials 
involved the subtraction of the number 2 to prevent subjects 
from anticipating the next operation. Subjects were asked to 
perform subtraction mentally without speaking or moving 
the tongue or lips, and to indicate with a button press when 
they completed a subtraction operation. Two runs of the task 
were performed.
Image acquisition
Scanning was performed using a 3 Tesla MR scanner (Signa 
Excite HD; GE Healthcare, Waukesha, WI) located at the 
Seaman Family MR Research Centre. Head movement was 
restricted with foam padding. An automated shimming routine 
was performed to optimize magnetic ﬁ  eld homogeneity. A gra-
dient echo T2*-weighted echo planar imaging (EPI) sequence 
was used to acquire f MRI data (TR/TE = 3000/30 ms, ﬁ  eld of 
view = 24 cm, 96 × 96 matrix, ﬂ  ip angle = 50°, 20 6-mm thick 
slices). During the 2-back task, 90 volumes were collected, 
and during the mental subtraction task, 130 volumes were 
collected. A T1-weighted high-resolution volume using a 3D 
acquisition [spoiled gradient echo (SPGR) sequence: repetition 
time (TR) = 21 ms, minimum echo time (TE), ﬁ  eld of view 
(FOV) = 24 × 18 × 12 cm, matrix size = 320 × 224 × 64] was 
used for anatomical registration of the f MRI data.
Image data analyses
Analysis involved four complete data sets from each of seven 
PSD patients, two incomplete data sets from each of two PSD 
patients (one session per drug condition), and one complete 
data set from each of nine healthy volunteers. Two PSD 
patients declined to participate in all four sessions because 
of the effects of depression and stress related to the cognitive 
tasks and imaging. Analysis of all scans was carried out using 
FEAT (F MRI Expert Analysis Tool) Version 5.4, part of FSL 
(F MRIB’s Software Library, http://www.fmrib.ox.ac.uk/fsl). 
After motion correction using MCFLIRT (Jenkinson et al 
2002) and spatial smoothing (Gaussian kernel FWHM 8 mm), 
time-series statistical analyses were carried out using FILM 
(FMRIB’s Improved Linear Model) with local autocorrelation 
correction (Woolrich et al 2001). Speciﬁ  cally, estimates of 
the average magnitude of activity within each image pixel in 
response to each type of trial block (ie, SIMSUB_1, SIMSUB_7, 
SERSUB_1, and SERSUB_7 for the subtraction task, and task 
versus rest for the 2-back task) were generated using models 
of the expected hemodynamic response (a normalized gamma 
function convolved with the binary timing of the corresponding 
block type and including the temporal derivative).
Higher-level planned comparisons were then carried out 
using a General Linear Mixed Effects using FLAME (FMRIB’s 
Local Analysis of Mixed Effects). For the 2-back data, mean 
activity during the task was determined for each of the placebo-
treated, MP-treated, and control groups by determining clusters 
of brain activity exceeding Z = 2.3 (p = 0.01) and a corrected 
cluster size of   k = 12. For the mental subtraction data, the 
contrast between the serial and simple subtraction conditions 
[ie, (SERSUB_1 + SERSUB_7) versus (SIMSUB_1 + SIM-
SUB + 7)] was determined for each of the placebo-treated, 
MP-treated, and control groups by determining clusters of 
brain activity exceeding Z   2.3 (p = 0.01) (uncorrected for 
multiple comparisons) and a corrected cluster size of k = 12. 
Further for the 2-back data, a within-group comparison 
was performed for the patients using regressors to model 
(1) a difference in activity between MP and placebo conditions, 
(2) a difference in activity between the ﬁ  rst and second placebo 
condition, (3) a difference in activity between the ﬁ  rst and 
second MP condition, and a regressor of noninterest to account 
for linear trend in activity across all four sessions. Contrast 
images for each of the regressors of interest were generated 
using signiﬁ  cant clusters determined by Z   2.3 (p = 0.01) 
(uncorrected for multiple comparisons) and a corrected cluster 
size of k = 12. An identical analysis was performed for the 
subtraction data using the SIMSUB versus SERSUB contrast 
estimate. Between-group comparisons were made between 
the healthy controls and each of the MP-treated and placebo-
treated patient groups for mean activity during the 2-back task 
as well as for the SERSUB versus SIMSUB contrast.Neuropsychiatric Disease and Treatment 2008:4(6) 1255
Methylphenidate modulation of neural activity in post-stroke depression
Behavioral data analyses
Subject characteristics were analyzed using appropriate 
parametric (t-test) and nonparametric methods (Chi-square). 
A repeated measures analysis of variance (ANOVA) was 
used to analyze task performance data (number of errors and 
reaction time for 2-back task, reaction time for the subtraction 
task) with treatment condition (MP, placebo) and session (ﬁ  rst, 
second) as factors. The interaction between these two factors 
was also investigated. Pulse rate, blood pressure (diastolic and 
systolic), and HAM-D, VAS, MMSE scores were analyzed 
in the same manner. T-tests were performed to analyze the 
differences in performance data between healthy control and 
PSD patients during placebo and MP treatment separately, 
corrected for multiple comparisons. All statistical analyses 
were performed using SPSS statistical software version 9 for 
Windows (SPSS Inc., Chicago, IL, USA). A p value of less 
than 0.05 was considered as statistically signiﬁ  cant.
Results
Sample characteristics
Sample characteristics are presented in Table 1. All PSD 
patients participating in the study had stroke lesions involving 
either right or left middle cerebral artery territories. Among 
these patients, four had right hemispheric lesions and four 
had left hemispheric lesions, and one had bilateral infarcts. 
The infarcts in these patients involved frontal, parietal, and 
temporal regions, as well as subcortical areas including the 
basal ganglia, internal capsule and periventricular regions. 
Seven out of nine depressed stroke patients had co-morbid 
medical conditions including hypertension and diabetes 
mellitus, and they were taking medications for their medical 
conditions. Three patients had personal history of depression 
and two patients had family history of depression in the ﬁ  rst 
generation. None of the depressed patients were taking any 
antidepressants or psychotropic medications during the study. 
Only two patients were taking zopiclone 7.5 mg/d for insomnia, 
as needed. These patients had moderate to severe depression 
(HRSD scores: mean = 26.11, SD = 4.49), as well as minimal 
cognitive impairment (MMSE scores: mean = 28, SD = 2) 
and physical impairment (Barthel scores: mean = 87.78, SD 
= 19.22) at the time of investigation. There were no signiﬁ  cant 
differences in age [t(16) = −0.092, p = 0.93], gender (chi-square 
= 0.22, df = 1, p = 0.64), and years of education [t(16) = −0.477, 
p = 0.64) between the PSD and healthy comparison groups.
Behavioral responses
The analysis of performance measures showed no effect of drug 
or time or drug × time interaction for both the 2-back and mental 
subtraction tasks in depressed stroke patients. For the 2-back 
task, the main effects of drug (F = 1.91, df = 1.6, p = 0.22) 
and time ( F = 0.70, df = 1.6, p = 0.44), as well as drug × 
time interaction (F = 1.60, df = 1.6, p = 0.25) on the number 
of errors were nonsigniﬁ  cant. Further, there was no effect of 
drug (F = 0.01, df = 1.6, p = 0.87) or time (F = 0.08, df = 1.6, 
p = 0.79) or drug × time interaction (F = 2.05, df = 1.6, p = 0.20) 
on subject reaction time. Similarly, for the subtraction task, 
there was no effect of drug (F = 0.56, df = 1.6, p = 0.48) or 
time (F = 0, df = 1.6, p = 0.99) or drug × time interaction 
(F = 1.42, df = 1.6, p = 0.28) on reaction time; there was no 
accuracy measure for the subtraction task. The performance 
measures of control subjects were not signiﬁ  cantly different 
from PSD patients in the placebo or MP conditions [for RT 
in the 2-back task: MP vs HC (t = 1.59, df = 16, p = 0.13), 
placebo vs HC (t = 1.51, df = 16, p = 0.15); for errors: MP 
vs HC (t = 0.54, df = 16, p = 0.60), placebo vs HC (t = 0.71, 
df = 16, p = 0.49); for RT in the serial subtraction task: MP 
vs HC (t = 0.71, df = 16, p = 0.49); placebo vs HC (t = 0.83, 
df = 16, p = 0.42); for RT in the simple subtraction task: MP 
vs HC (t = 0.90, df = 16, p = 0.38), placebo vs HC (t = 0.64, 
df = 16, p = 0.53)].
Clinical responses
Means were replaced for missing values in two patients who 
did not complete all 4 scanning sessions. There was no effect 
of drug (F = 0.844, df = 1.8, p = 0.39) or time (F = 2.99, 
df = 1.8, p = 0.12) or drug × time interaction (F = 1.843, 
df = 1.8, p = 0.21) on HRSD in PSD patients. Further, 
there was no effect of drug (F = 1.62, df = 1.8, p = 0.24) or 
drug × time interaction ( F = 1.56, df = 1.8, p = 0.25), but 
there was an effect of time (F = 6.39, df = 1.8, p = 0.035) on 
VAS measures. VAS score on day 3 was lower than day 1 
regardless of treatment condition (mean difference between 
day 1 and day 3 was 0.619, SE = 0.245). None of the patients 
reported any adverse effects with either placebo or MP. 
MMSE measures did not show signiﬁ  cant effects of treatment 
(F = 1, df = 1.8, p = 0.35), time (F = 1, df = 1.8, p = 0.35) or 
drug × time interaction (F = 1, df = 1.8, p = 0.35).
Physiological responses
Means were replaced for missing values in two patients with 
incomplete data. Analysis of physiological measures in PSD 
patients showed a signiﬁ  cant effect of drug on pulse rate and 
a nonsigniﬁ  cant effect on systolic and diastolic blood pres-
sure. MP signiﬁ  cantly increased pulse rate compared to pla-
cebo in both sessions. Thus, there was a main effect of drug 
on heart rate (F = 6.81, df = 1.8, p = 0.031), but no effect of Neuropsychiatric Disease and Treatment 2008:4(6) 1256
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time (F = 0.19, df = 1.8, p = 0.67 ) or drug × time interaction 
(F = 0.044, df = 1.8, p = 0. 839) on the same measure. Regarding 
blood pressure responses, there was no effect of drug (F = 1.48, 
df = 1.8, p = 0.26; F = 0.61, df = 1.8, p = 0.46), or time ( F = 2.694, 
df = 1.8, p = 0.14; F = 0.29, df = 1,8, p = 0.61), or drug × time 
interaction (F = 0.768, df = 1.8, p = 0.41; F = 0.34, df 1.8, p = 0.58) 
on systolic and diastolic blood pressure, respectively.
FMRI data
Effects of MP and placebo on task-dependent 
brain activity in depressed stroke
To test whether there were signiﬁ  cant differences in task-
dependent activity between MP and placebo conditions, 
we compared whole brain activations during speciﬁ  c task 
conditions between MP and placebo treatment. Figure 1 shows 
brain activity related to the 2-back task for MP vs placebo 
contrasts (regions are summarized in Table 2). During the MP 
condition, relative to placebo, signiﬁ  cantly greater activity 
was detected in left prefrontal, right parietal, left temporal, 
posterior cingulate cortex (PCC), and bilateral cerebellar 
regions, and signiﬁ  cantly less activity was detected in rostral 
prefrontal cortex and left parietal regions. Figure 2 shows 
brain activity related to the serial   simple subtraction con-
dition for MP vs placebo contrasts (regions are summarized 
in Table 3). During the MP condition, relative to placebo, 
signiﬁ  cantly greater activity was detected in left dorsolateral 
prefrontal cortex (DLPFC), biparietal, bitemporal, bilateral 
cerebellar regions as well as hippocampus, parahippocampus, 
thalamus, insula, and putamen. For both the 2-back and the 
serial   simple subtraction task conditions, there was signiﬁ  -
cant activity during the MP condition in prefrontal, parietal, 
temporal and cerebellar regions, which was greater during 
the serial   simple subtraction task condition than during the 
2-back task. Further, activations in subcortical structures were 
seen only for the serial   simple subtraction contrast.
Effects of MP and placebo on task-dependent brain 
activity in depressed stroke compared with healthy 
controls
To examine whether short-term MP treatment improves or 
normalizes the baseline task-dependent impairments in PSD, 
we looked at the changes in task-dependent brain activity 
(increase, decrease or no signal changes) during each of the 
MP and placebo conditions compared to healthy controls. For 
the 2-back task (Table 2, Figure 3), relative to healthy controls, 
PSD patients during placebo treatment showed less activity in 
bilateral superior prefrontal, right superior parietal, and right 
superior temporal regions, as well as left cerebellum. How-
ever, during MP treatment, the baseline lesser activities in left 
cerebellum and the right superior temporal gyrus were normal-
ized. Further, the baseline reductions in activities in parietal and 
prefrontal areas seemed to improve with MP treatment.
For the serial   simple subtraction task condition 
(Table 3, Figure 4), relative to healthy controls, PSD patients 
during placebo treatment showed less brain activity in left 
prefrontal, bitemporal, bioccipital, and left caudate regions, 
whereas during MP treatment, these baseline reductions 
in brain activity disappeared. Further, relative to healthy 
controls, greater activity was observed in right cuneus, 
hippocampus and anterior cerebellum in PSD patients.
Effect of time on task-dependent brain 
activity during MP and placebo conditions
Taking into account the effect of repeat testing on task 
related brain activity, we examined the changes in brain 
activity between the first session (day 1) and second 
session (day 3) during placebo and MP treatment separately 
(Table 4). In the MP condition, the second session of the 
serial   simple subtraction condition produced greater 
activity in the anterior cerebellum compared to ﬁ  rst session, 
whereas in the placebo condition, there was greater activity 
in session 2 than session 1 in prefrontal occipital cortices and 
posterior cerebellar regions. There were no regions exhibiting 
less activity in session 2 compared to session 1 for either of 
the placebo or MP conditions. For the 2-back task, in the 
MP condition, there was greater activity in session 2 than 
session 1 within the lingual gyrus and less activity in several 
brain regions including prefrontal (BA 6,9,44,47), parietal 
regions (BA 7,40), anterior cingulate cortex, temporal regions 
(BA 22,21,38), thalamus, hippocampus, parahippocampus 
substantia nigra and amygdala. However, in the placebo 
condition, there was greater activity in session 2 compared 
to session 1 in prefrontal (BA 6, 9) and temporal regions 
(BA 21,22), as well as cerebellum and insula, and less activity 
in prefrontal regions (BA 6,8,10), parietal area (BA 7,40), 
and precuneus. In summary, there was a differential effect 
of repeated sessions on task speciﬁ  c brain activity between 
MP and placebo conditions.
Discussion
Our results indicate that in PSD patients, short-term MP treat-
ment increases task relevant activity in several brain regions 
during the performance of 2-back and mental subtraction tasks. 
During MP treatment, both cognitive tasks recruited prefron-
tal, parietal, temporal, and cerebellar regions known to par-
ticipate in working memory, calculation and attention related Neuropsychiatric Disease and Treatment 2008:4(6) 1258
Ramasubbu and Goodyear
Figure 1 2-Back task group contrast maps for methylphenidate (MP) and placebo (PL) conditions in patients with post-stroke depression.
information (Paulesu et al 1993; Fiez et al 1996; Rueckert et al 
1996; Jonides et al 1998; Burbaud et al 1999; Ranganath et al 
2004; Chen and Desmond 2005; Owen et al 2005). Further, 
healthy subjects activated most of these regions to a greater 
extent than PSD patients during placebo treatment. When PSD 
patients were given short-term MP treatment, they recruited 
these regions to a similar degree as the healthy subjects, 
especially during the subtraction task. Contrary to our expecta-
tions, the enhancement of cognitive neural effects due to MP 
treatment was not related to improvement in performance or 
mood symptoms in these PSD patients. Overall, these ﬁ  nd-
ings suggest that short-term MP treatment may enhance and 
normalize activity in cognitive neural networks independent 
of its effects on performance or mood measures.
MP-modulated neural activity during the cognitive task 
performance could be mediated predominantly by dopamine 
and norepinephrine mechanisms, as it enhances dopamine and 
norepinephrine neurotransmissions by blocking dopamine 
and norepinephrine transporters, and by increasing dopamine 
and norepinephrine levels in the brain (Kuczemski and Segal 
1997). In support of this notion, there is evidence that MP 
increases task-dependent dopamine release during cognitive 
activation (Volkow et al 2001, 2004). Furthermore, dopamine 
and norepinephrine neurotransmitter systems have been 
Figure 2 Serial subtraction task group contrast maps for methylphenidate (MP) and placebo (PL) conditions patients with post-stroke depression.Neuropsychiatric Disease and Treatment 2008:4(6) 1259
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Table 2 Group contrasts for brain activity during the 2-back task*
Brain Regions Brodmann area Z Score Talairach Coordinates (mm)
XYZ
MP   Placebo
L Superior frontal gyrus 6 3.41 −8 −14 68
L Medial frontal gyrus 6 3.61 −10 45 4
L Precentral gyrus 3 3.17 −36 −4 32
R Postcentral gyrus 3 3.72 40 −26 58
L Posterior cingulate 31 3.37 −26 −64 20
L Superior temporal gyrus 39 3.14 −42 −50 24
L Inferior temporal gyrus 20 2.95 −60 10 −36
L Parahippocampal gyrus 37 3.33 −24 −46 −6
L Middle occipital gyrus 18 3.58 −40 −80 −8
L Cerebellum 3.44 −8 −60 −26
R Cerebellum 3.46 −14 −60 −40
Placebo   MP
L Superior frontal gyrus 8 3.44 −6 38 54
L Superior frontal gyrus 11 3.72 −14 56 −12
L Medial frontal gyrus 10 3.77 −16 58 −2
R Medial fontal gyrus 6 3.07 60 0 44
L Superior parietal lobe 7 3.55 −14 −74 58
R Middle occipital gyrus 19 3.52 44 −74 8
HC   Placebo
R Superior frontal gyrus 6 3.12 4 8 64
L Superior frontal gyrus 6 4.2 −10 16 50
R Superior parietal lobule 7 4.99 28 −54 54
R Postcentral gyrus 3 3.28 62 −20 36
R Postcentral gyrus 40 3.45 60 −22 22
R Superior temporal gyrus 42 2.97 56 −32 14
L Cerebellum 2.89 −2 −62 −28
Placebo   HC
L Superior frontal gyrus 11 3.42 −26 52 −16
HC   MP
R Superior frontal gyrus 6 3.29 4 8 64
L Superior frontal gyrus 6 4.41 −10 16 50
R Superior parietal lobule 7 4.4 28 −54 54
R Postcentral gyrus 40 2.95 60 −22 22
MP   HC
L Superior frontal gyrus 10 3.68 −12 68 −2
L Superior frontal gyrus 11 3.36 −36 46 −2
Abbreviations: MP, methylphenidate; HC, health control; R, right; L, left.
Notes: *Activations were signiﬁ  cant at the threshold Z = 2.3 (P = 0.01uncorrected for multiple comparisons), K = 12 voxels.
implicated in working memory processing, and arithmetic 
task performance (Mehta et al 2000; Volkow et al 2004).
MP effects on BOLD responses related to cognitive 
tasks could be complicated by its effects on blood pressure, 
and heart rate. MP enhances blood pressure and heart rate 
by increasing the bioavailability of dopamine (Volkow 
et al 2002). Our results suggest an increase in pulse rate in 
MP condition. Further, MP may potentially disrupt neural Neuropsychiatric Disease and Treatment 2008:4(6) 1260
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activity and ﬂ  ow coupling due to its direct global and regional 
effect on cerebral perfusion. Hence the observed MP-related 
increases in BOLD responses might be confounded by MP’s 
direct pharmacological effects on cerebral hemodynamics 
or cardiovascular system. Although this possibility can not 
be completely ruled out, previous data suggest that 20 mg 
oral dose of MP does not alter hemodynamic responses to 
task activation when task conditions are comparable (Rao 
et al 2000). Another study investigating the f MRI and EEG 
measures of the dopaminergic drug effects on brain function 
showed consistency in both measures implying that BOLD-
fMRI responses may not necessarily be inﬂ  uenced by drug 
effects on cerebral perfusion (Arthurs et al 2004).
The observed MP-induced increases in left premotor 
(BA6) and left DLPFC (BA9) activity during cognitive 
task conditions are consistent with their suggested role in 
information management, executive control of working 
memory, serial subtraction and 2-back task processing 
(Burbaud et al 1999; Hugdahl et al 2004; Owen et al 
2005). Further, these regions have been shown to have 
dense dopaminergic and noradrenergic innervation (Gaspar 
et al 1989). Parietal lobe activity (BA 7,40) seen during 
subtraction is consistent with its implicated role in storage 
and retrieval processing of working memory and arithmetic 
calculation (Jonides et al 1998; Burbaud et al 1999). Our 
ﬁ  nding of MP-induced activity in cerebellar and temporal 
regions for both tasks merits further discussion. The task 
speciﬁ  c activity in the cerebellum during the MP condition 
is consistent with a large number of studies implicating the 
role of the cerebellum in working memory task performance 
and in the modulation of forebrain dopamine blood ﬂ  ow 
(Paulesu et al 1993; Fiez et al 1996; Chen and Desmond 
2005; Udo et al 2007). Fronto-cerebellar networks have been 
postulated to be involved in the articulatory control system, 
and parietal-cerebellar networks have been postulated to 
be involved in the phonological storage system during 
Figure 4 Serial subtraction task group contrast maps for healthy controls vs. patients with post-stroke depression in placebo (PL) and methylphenidate (MP) conditions.
Figure 3 2-Back task group contrast maps for healthy control (HC) vs. patients with post-stroke depression in placebo (PL) and methylphenidate (MP) conditions.Neuropsychiatric Disease and Treatment 2008:4(6) 1261
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Table 3 Group contrasts for brain activity in the serial   simple condition*
Brain Regions Brodmann area Z Score Talairach coordinates (mm)
XY Z
MP   Placebo
L Medial frontal gyrus 9 3.16 −4 56 8
R Precentral gyrus 6 3.51 4 −26 58
L Superior parietal lobe 40 3.19 −32 −4 60
R Superior parietal lobe 7 3.32 18 −54 56
L Posterior cingulate gyrus 31 2.88 −2 −40 40
R Precuneus 7 2.87 12 −58 40
L Superior temporal gyrus 42 2.81 −56 −32 18
R Superior temporal gyrus 22 3.14 66 0 −2
R Middle temporal gyrus 21 3.46 68 −36 0
L Middle temporal gyrus 37 2.59 −60 −50 −10
L Temporal pole 38 3.53 −46 16 −30
R Temporal pole 38 2.56 44 22 −30
L Hippocampus 4.07 −22 −14 −20
R Parahippocampal gyrus 19 3.55 32 −20 −24
L Lateral occipital cortex 19 3.02 −24 −74 34
R Lateral occipital cortex 18 3.63 44 −74 −4
R Thalamus (medial dorsal nucleus) 3.5 12 −20 12
R Putamen 3.68 32 2 0
R Insula 13 3.2 30 10 −2
L Fusiform gyrus 19 4.38 −32 −68 −12
R Anterior cerebellum 3.47 20 −46 −22
R Posterior cerebellum 3.72 20 −86 −26
L Anterior cerebellum 2.94 −42 −48 −28
Placebo   MP -– – – –
HC   Placebo
L Inferior frontal gyrus 45 2.86 −44 34 0
L Precentral gyrus 6 2.78 −56 −6 48
R Postcentral gyrus 1 3.03 60 −18 48
R Superior temporal gyrus 42 2.61 68 −30 12
L Inferior temporal gyrus 37 2.89 −50 −60 −18
L Lateral occipital cortex 19 2.7 −54 −76 8
R Inferior occipital cortex 19 2.96 28 −90 −6
L Caudate 2.79 −20 16 14
Placebo   HC –– – – –
HC   MP -– – –
MP   HC
R Cuneus 18 2.67 16 −80 18
L Hippocampus 3.13 −24 −14 −22
R Parahippocampal gyrus 34 2.94 12 2 −22
L Anterior cerebellum 2.65 12 2 −22
Abbreviations: MP, methylphenidate; HC, health control; R, right; L, left.
Notes: *Activations were signiﬁ  cant at the threshold Z = 2.3 (P = 0.01uncorrected for multiple comparisons), K = 12 voxels.Neuropsychiatric Disease and Treatment 2008:4(6) 1262
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Table 4 Effects of repeated tests on brain activity in placebo and MP conditions*
Anatomy Brodmann area Z Score Talairach coordinates (mm)
XYZ
1. Serial   Simple Task
Placebo (Day 1   Day 3)
No activations −− − − −
Placebo (Day 3   Day 1)
L Superior frontal gyrus 6 2.71 −8 20 56
R Frontal pole 10 3.72 2 62 8
R Lateral occipital cortex 19 2.71 50 −18 2
R Posterior cerebellum 2.61 26 −78 −20
R Posterior cerebellum 3.29 44 −58 −38
MP (Day 1   Day 3)
No activations −− − − −
MP (Day 3   Day1)
R Anterior cerebellum 3.47 32 −56 −22
2. 2-Back   Control Task
Placebo (Day 1   Day 3)
L Middle frontal gyrus 6 4.15 −34 −4 −66
R Inferior parietal lobule 40 3.6 44 −50 62
R Superior parietal lobule 7 4.02 34 −70 56
R Precentral gyrus 6 3.74 48 0 52
L Superior parietal lobule 7 3.24 −26 −72 50
L Precuneus 19 4.59 −22 −84 42
R Middle frontal gyrus 8 3.47 46 20 42
R Superior frontal gyrus 10 3.91 36 62 −8
Placebo (Day 3   Day 1)
L Medial frontal gyrus 6 3.53 −10 −22 72
R Medial frontal gyrus 6 3.31 16 0 62
R Middle frontal gyrus 9 3.59 30 34 24
R Superior temporal gyrus 22 3.34 62 −36 18
L Insula 13 3.06 −34 61 2
R Middle temporal gyrus 21 3.64 62 4 −24
R Cerebellum 3.32 16 −56 −34
MP (Day1   Day 3)
L Superior frontal gyrus 6 4.51 −2 −6 72
R Superior frontal gyrus 6 3.23 30 4 64
R Inferior parietal lobule 40 4.24 38 −52 46
R Precuneus 7 4.91 12 −74 50
L Inferior parietal lobule 40 3.11 −32 −66 58
L Cingulate gyrus 24 3.99 −6 64 6
L Anterior cingulate 24 4.1 −2 22 44
L Precentral gyrus 6 4.75 −38 −8 42
R Precentral gyrus 44 3.8 54 8 12
L Inferior frontal gyrus 44 3.95 −58 81 2
L Thalamus 4.12 −46 14 12
(Continued)Neuropsychiatric Disease and Treatment 2008:4(6) 1263
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working memory processing (Chen and Desmond 2005). 
The increased activity in temporal regions during the MP 
condition could be explained based on its role in working 
memory maintenance (Ranganath et al 2004).
The other brain regions that were more highly activated 
during the MP condition include PCC, hippocampus 
and parahippocampus. The PCC activity in our study is 
consistent with previous studies reporting its participation 
in serial subtraction and working memory performance 
(Ouchi et al 2004; Hampson et al 2006). PCC plays a 
role in multimodal associative functioning during serial 
subtraction and has functional connections with anterior 
cingulate cortex during working memory tasks (Ouchi 
et al 2004; Hampson et al 2006). The hippocampal and 
parahippocampal activity during MP treatment is in 
accordance with its role in short term memory consolida-
tion and encoding in working memory processing, and in 
serial subtraction task performance (Harrington et al 2004; 
Mainy et al 2007; Sammer et al 2007). MP-induced activity 
was also seen in thalamus, putamen, insula, fusiform 
gyrus and visual association cortex during subtraction, 
and their participation in attention, working memory and 
arithmetic processing has been documented in previous 
reports (Ojemann 1974; Honey et al 2003; Chang et al 
2007; Mayer et al 2007; Sammer et al 2007).
An important ﬁ  nding of our study is that compared to 
healthy controls, the placebo condition exhibited less activity 
in frontal, parietal, temporal and cerebellar regions during the 
2-back task and in frontal, parietal, temporal occipital and 
caudate regions during the serial subtraction task, whereas 
MP treatment showed no reduction in brain activity during 
the serial subtraction task and improvement in activity 
during the 2-back task. Considering that placebo related 
decreases in task-dependent activity are baseline deﬁ  cits 
due to the negative effects of depression and anterior stroke 
lesions on functional cognitive neural networks, MP-related 
improvement in cognitive brain activity suggests that short 
term treatment with MP may improve functional cognitive 
networks, and also seem to normalize the activation within 
these networks. Further, MP related increases in activity in 
cuneus, hippocampus, parahippocampus and cerebellum 
during serial subtraction in depressed stroke patients 
compared to healthy controls might reﬂ  ect compensatory 
mechanisms, especially in memory functions.
Our results showed that the brain adaptive responses to 
repeat cognitive testing could be inﬂ  uenced by short-term 
MP treatment. MP treatment seemed to inﬂ  uence the brain 
adaptive responses to repeat testing, as it showed greater 
repetition suppression (less activity in the second session 
than the ﬁ  rst session) for the 2-back task and less activa-
tion in the second session for serial subtraction than dur-
ing placebo treatment. Although the practice effect and 
task difﬁ  culty were controlled and performance measures 
were comparable, the brain adaptive responses for repeat 
Table 4 (Continued)
Anatomy Brodmann area Z Score Talairach coordinates (mm)
XYZ
L Substantia nigra 4.05 −12 −18 6
R Middle temporal gyrus 22 3.74 −10 −18 −8
R Middle temporal gyrus 21 3.99 60 −40 6
R Superior temporal gyrus 22 3.61 −66 −40 4
L Putamen/lentiform nucleus 3.45 −26 −2 −6
R Claustrum 3.3 36 −2 −6
R Superior temporal gyrus 38 3.62 56 14 −14
R Inferior frontal gyrus 47 3.25 36 16 −14
L Amygdala 3.7 −26 −4 −18
R Hippocampus 3.77 32 −10 −22
R Parahippocampal gyrus 28 3.96 20 −10 −22
Brainstem 3.9 6 −14 −24
MP (Day 3   Day 1)
L Lingual gyrus 19 3.26 −8 −62 −10
Abbreviations: MP, methylphenidate; HC, health control; R, right; L, left.
Notes: *Activations were signiﬁ  cant at the threshold Z = 2.3 (P = 0.01 uncorrected for multiple comparison), K = 12 voxels.Neuropsychiatric Disease and Treatment 2008:4(6) 1264
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testing were different between treatment conditions. This 
could be explained partly by the pharmacological effect of 
repeat dosing of MP on brain responses, which is consistent 
with the previous observation of decreased brain metabolic 
responses between single and repeated doses of MP (Volkow 
et al 1998). Further, the MP treatment-related decreases in 
brain responses in the second session could be related to the 
improved adaptation to the task difﬁ  culty. This interpretation 
is congruent with previous studies showing significant 
attenuation in frontal responses to cognitive load with MP 
administration (Bullmore et al 2003).
Some methodological issues in relevance to the 
negative ﬁ  ndings of this study need to be addressed. The 
failure to show enhancement in cognitive performance 
and improvement in mood during the MP condition could 
be due to small sample size resulting in type II error and 
other methodological reasons. We excluded PSD patients 
with severe cognitive impairment, which might explain the 
comparable cognitive performance measures between PSD 
patients during the placebo condition and healthy controls. 
Since the effect of MP on cognitive performance may be 
dependent on baseline deﬁ  cits, we did not ﬁ  nd improvement 
with MP treatment on performance measures. However, 
our results were consistent with previous studies reporting 
dissociation between drug related performance measures 
and brain activity (Shafritz et al 2004), and therefore it is 
conceivable that functional imaging may be a more sensitive 
or early marker of drug effects than behavioral measures of 
cognitive task performance. Contrary to previous reports, 
we did not ﬁ  nd any signiﬁ  cant improvement in depression 
symptoms with 3 days of MP treatment with conventional 
doses of 20 mg/day (Masand et al 1991). The possible 
reasons for this discrepancy could be that we used MP as a 
monotherapy in our study whereas in previous studies, MP 
was used as an add-on treatment to antidepressants in major-
ity of the patients. The absence of drug effects on clinical 
measures could also be due to inadequate dosage and duration 
of treatment in these selected patients.
The other limitations were that the ﬁ  ndings of the study 
should not be generalized beyond the sample analyzed due to 
small sample size and heterogeneity in lesions locations. Since 
the study design was complex and involved four imaging 
sessions, there were signiﬁ  cant difﬁ  culties in the recruitment 
of depressed stroke patients. There was also no evaluation of 
the pharmacokinetics of MP, although the literature suggests 
considerable inter-subject variability in the pharmacokinetics 
of MP as well as a linear dose-response relationship between 
MP plasma concentration and brain activity during cognitive 
tasks (Muller et al 2005). The MP related increases in brain 
activity could have been inﬂ  uenced by other medications 
that the stroke patients were taking. However, within-
subject crossover design employed in our study was likely to 
minimize the above-mentioned shortcomings. In the absence 
of comparative data from nondepressed stroke patients, it is 
not possible to interpret whether these results are related to 
post stroke depression or to stroke in general regardless of 
depression. The healthy subjects were scanned only one time 
in an unmedicated condition, which precluded an accurate 
analysis of drug effects on repeated assessments (such as 
habituation and learning). Although we used the placebo 
condition as baseline, fMRI ﬁ  ndings during the placebo 
condition cannot be considered as baseline deﬁ  cits given the 
reported placebo related activity in fMRI studies (Benedetti 
et al 2005). Because of heterogeneity in lesion location in our 
small sample, we did not assess ipsilateral and contralateral 
activity separately.
Summary
Despite these methodological limitations, this is the ﬁ  rst study 
to our knowledge to demonstrate the beneﬁ  cial effects of MP 
on functional cognitive neural networks in patients with PSD. 
These brain-based results are important for understanding the 
beneﬁ  cial effects of MP in stroke depression, particularly 
the neural mechanisms of its cognitive effects, which may 
have important clinical treatment implications in depression 
associated with cognitive impairment. The observed 
improvement and normalization in cognitive neuronal 
network with short term treatment of MP may need further 
evaluation in a large sample to determine its clinical relevance 
as well as its potential role in cognitive rehabilitation in 
depressed and nondepressed stroke patients.
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